Current Atherosclerosis Reports

Papers
(The TQCC of Current Atherosclerosis Reports is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients73
APOA1: a Protein with Multiple Therapeutic Functions71
Social Determinants of Health and Cardiovascular Disease: Current State and Future Directions Towards Healthcare Equity66
COVID and Cardiovascular Disease: What We Know in 202165
Food Insecurity and Cardiovascular Disease Risk64
Periodontal Inflammation and the Risk of Cardiovascular Disease60
Trimethylamine N-Oxide (TMAO), Diet and Cardiovascular Disease57
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis56
CD36 in Atherosclerosis: Pathophysiological Mechanisms and Therapeutic Implications56
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?52
High-Density Lipoproteins and Serum Amyloid A (SAA)49
Time-Restricted Eating to Improve Cardiovascular Health44
A Review of the Relationship Between CTRP Family and Coronary Artery Disease42
Lipid Lowering Drugs: Present Status and Future Developments41
New Pharmacological Approaches to Target PCSK940
The Role of the Gut Microbiota in Coronary Heart Disease40
The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review39
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions38
Microparticles (Exosomes) and Atherosclerosis37
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets36
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician36
Statins and Inflammation34
The Long Non-coding Road to Atherosclerosis34
Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care33
Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia33
The Association Between Periodontitis and Cardiovascular Disease: an Update32
Phytosterols and Cardiovascular Disease30
Exosomes: Multifaceted Messengers in Atherosclerosis30
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond30
Clinical Pharmacology of Statins: an Update30
More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis30
Targeting Inflammation to Reduce Residual Cardiovascular Risk29
Digital Health Innovations to Improve Cardiovascular Disease Care29
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues28
HDL-small RNA Export, Transport, and Functional Delivery in Atherosclerosis27
Association Between Caliber of Retinal Vessels and Cardiovascular Disease: a Systematic Review and Meta-Analysis27
Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications26
Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials25
Nutrition and Gastrointestinal Microbiota, Microbial-Derived Secondary Bile Acids, and Cardiovascular Disease25
Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context24
Bempedoic Acid: for Whom and When24
High HDL-Cholesterol Paradox: SCARB1-LAG3-HDL Axis23
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?23
The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia23
Menopausal Hormone Therapy: a Comprehensive Review23
Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics23
Overweight, Obesity, and CVD Risk: a Focus on Visceral/Ectopic Fat22
Statins in a Distorted Mirror of Media22
Structural Basis for Vital Function and Malfunction of Serum Amyloid A: an Acute-Phase Protein that Wears Hydrophobicity on Its Sleeve22
Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors22
Apolipoprotein E and Atherosclerosis21
Understanding Immigration as a Social Determinant of Health: Cardiovascular Disease in Hispanics/Latinos and South Asians in the United States21
The Difference Between High Density Lipoprotein Subfractions and Subspecies: an Evolving Model in Cardiovascular Disease and Diabetes20
Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis20
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease20
Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment20
Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis19
Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease19
Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis19
Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents19
RNA Silencing in the Management of Dyslipidemias18
Spontaneous Coronary Artery Dissection: Latest Developments and New Frontiers18
The Genetic Basis of Hypertriglyceridemia18
Dyslipidemia Management in Pregnancy: Why Is It not Covered in the Guidelines?18
Nutrient Profiling Systems, Front of Pack Labeling, and Consumer Behavior18
Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease17
Lipid Phenotypes and DNA Methylation: a Review of the Literature17
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?17
Lipoprotein (a): When to Measure and How to Treat?17
Inclisiran: How Widely and When Should We Use It?17
Ambient Air Pollution and Atherosclerosis: Recent Updates17
Lp(a): a New Pathway to Target?17
LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective17
Metabolomic Biomarkers of Healthy Dietary Patterns and Cardiovascular Outcomes16
The Role of Statins in Current Guidelines16
Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?16
MicroRNAs and Circular RNAs in Lipoprotein Metabolism16
Obesity Management in Cardiometabolic Disease: State of the Art16
Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)15
Inflammatory Links Between Hypertriglyceridemia and Atherogenesis15
Ultra-processed Foods and Cardiometabolic Health Outcomes: from Evidence to Practice15
Managing Ischemic Heart Disease in Women: Role of a Women’s Heart Center14
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?14
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis14
Sex Differences in Coronary Atherosclerosis14
The Role of High-Density Lipoprotein Cholesterol in 202214
The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis14
The Role of Sex-Specific Risk Factors in the Risk Assessment of Atherosclerotic Cardiovascular Disease for Primary Prevention in Women14
Contributions of Food Environments to Dietary Quality and Cardiovascular Disease Risk13
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management13
Genetic Risk Factors of Intracranial Atherosclerosis13
The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia13
RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases13
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?13
Dietary Influences on Atherosclerotic Cardiovascular Disease Risk13
Novel RNAi-Based Therapies for Atherosclerosis13
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men13
Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well13
Gene-Environment Interactions for Cardiovascular Disease13
0.028803825378418